Insight & Intelligence™ : Sep 18, 2012
GEN Ten: Young Guns of Biopharma
Which biopharm execs haven't reached middle age yet? Find out here.
George Bernard Shaw once commented that “Youth is wasted on the young.” But the GEN TEN list of under-40 biopharma hotshots indicates, instead, that youth is being served. From positions as president and CEO to division head and co-founder, young professionals under 40 are already making an impact on the global bioindustry. And they will certainly play key roles in shaping its future.
Below is a list of biopharma executives under 40 years old, as verified by their employers or as reported in local or trade publications that have included them in their own “Under 40” lists within the past year.
Vance Vanier, M.D.
CEO, Navigenics (acquired by Life Technologies in July)
38 years old1
Chad Robins
CEO & President, Adaptive Biotechnologies
38 years old
Brian McVeigh
VP, Worldwide Business Development, Transactions & Investment Management, GlaxoSmithKline
39 years old2
Andrew Asa Hindman
President & CEO, Tobira Therapeutics
39 years old
Al Hawkins
CEO, Milo Biotechnology and VP of Business Development, BioMotiv
37 years old
Uday Gupta
CEO, Global Cell Solutions and ProteiosBio
38 years old on June 13
Jeff George
Division Head, Sandoz, Novartis
39 years old
Van Bui
Treasurer, Genentech
38 years old4
Steven Axon
VP of Business Development, North America; Head of Global Business Development, Fertility, and Endocrinology, EMD Serono
37 years old
Adeyemi (Yemi) Adesokan, Ph.D.
Co-Founder & CEO, Pathogenica
35 years old
1 Listed as 38 years old in the “40 Under 40” list published Feb. 24, 2012, by the San Francisco Business Times.
2 Verified by a GSK spokeswoman through a colleague but not directly with Mr. McVeigh.
3 Listed as 38 years old in the “40 Under 40” list published June 2012 by Medical Device & Diagnostic Industry (MD+DI).
4 Listed as 37 years old in the “40 Under 40” list published October 2011 by Treasury & Risk.